Learning from real-world treatment of IgA nephropathy with iptacopan or atrasentan
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study collects real-world information from people with IgA nephropathy who are being treated with one of two medicines, iptacopan or atrasentan. The goal is to understand how these treatments work in everyday practice, which may help improve care for others with the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy that confirms IgA nephropathy.
- You must be 18 years or older.
- Your doctor must decide that you can be treated with iptacopan or atrasentan.
- You cannot be on any investigational drugs or in other clinical trials during the study.
- You should not be pregnant or have medical conditions that make these medicines unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This study tests an investigational drug called SCTC21C for people with IgA nephropathy, a kidney disease caused by abnormal antibodies. The drug aims to target and reduce these harmful antibodies, which may help slow kidney damage.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.